2. Academic Validation
  3. The RBPJ/DAPK3/UBE3A signaling axis induces PBRM1 degradation to modulate the sensitivity of renal cell carcinoma to CDK4/6 inhibitors

The RBPJ/DAPK3/UBE3A signaling axis induces PBRM1 degradation to modulate the sensitivity of renal cell carcinoma to CDK4/6 inhibitors

  • Cell Death Dis. 2022 Apr 2;13(4):295. doi: 10.1038/s41419-022-04760-6.
Wentao Liu  # 1,  Bin Zhang  # 2,  Dan Zhang  # 2,  Feng Guo 2,  Kun Ye 1,  Liang Zhu 3 4,  Xin Jin 5 6
Affiliations

Affiliations

  • 1 Department of Urology, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China.
  • 2 Cancer center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, China.
  • 3 Department of Urology, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China. zhuliang@csu.edu.cn.
  • 4 Uro-Oncology Institute of Central South University, 430022, Changsha, Hunan, China. zhuliang@csu.edu.cn.
  • 5 Department of Urology, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China. jinxinxy2@csu.edu.cn.
  • 6 Uro-Oncology Institute of Central South University, 430022, Changsha, Hunan, China. jinxinxy2@csu.edu.cn.
  • # Contributed equally.
PMID: 35368029 DOI: 10.1038/s41419-022-04760-6
Abstract

Renal cell carcinoma (RCC) is a kind of malignant tumor originating from the renal tubular epithelium. Approximately 30% of patients with renal Cancer are found to have metastasis when first diagnosed. Exploring Other effective treatment methods in addition to surgery is an urgent need in the research field of renal cell carcinoma. Polybromo 1 (PBRM1) is the second most mutated gene in RCC, with a mutation rate of ~40%. Notably, the posttranscriptional modification of PBRM1 in RCC is unclear. In this study, we performed unbiased mass spectrometry of PBRM1 and identified ubiquitin-protein Ligase E3A (UBE3A), an extensively studied E3 Ligase that can bind with PBRM1 and regulate the stability of PBRM1 in renal Cancer cells. We further found that RBPJ/DAPK3 modulated the E3 Ligase activity of UBE3A by interfering with the PKA phosphorylation of UBE3A. Finally, we demonstrated that the RBPJ/DAPK3/UBE3A/PBRM1/p21 axis contributed to the sensitivity of renal Cancer cells to CDK4/6 inhibitors. In addition, in combination with RBPJ inhibitors, CDK4/6 inhibitors showed synergistically enhanced effects on renal Cancer cells. In summary, we not only revealed a novel RBPJ/DAPK3/UBE3A/PBRM1/p21 signaling axis but also identified a combination strategy for overcoming the resistance of renal Cancer cells to CDK4/6 inhibitors.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z